Home Vesalius Cardiovascular Inc.

Vesalius Cardiovascular Inc.

Vesalius Cardiovascular Announces the Completion of a Successful Chronic Animal Study

The predetermined endpoints of the study were the absence of device or valve thrombosis and the absence of leaflet injury due to the device, and both endpoints were robustly confirmed upon completion of the study.